Conceptual Recognition of TDP-43–Associated Neurodegenerative Disease—Are We There Yet?

JAMA Neurology·August 24

Clinical Neurology Limited evidence Neurodegenerative Disease TDP-43 Proteinopathy Commentary Commentary / Perspective Editorial / Perspective

Summary

View source

What was studied

This appears to be a conceptual or perspective piece examining whether TDP-43–associated neurodegenerative disease has reached a stage of recognized clinical and biological definition as a distinct disease entity.

Study limitations

The paper was published only 6 days before today's date; the full text is not provided, limiting extraction of specific findings, data, or conclusions.

Related Questions

Explore related topics

What are the current diagnostic criteria for TDP-43 associated neurodegeneration?What biomarkers are currently available for detecting TDP-43 pathology in vivo?What is the current clinical criteria for diagnosing TDP-43 proteinopathy?How does TDP-43 pathology overlap across ALS, FTLD, and limbic-predominant age-related TDP-43 encephalopathy?How does TDP-43 proteinopathy overlap with ALS, FTLD, and LATE?How does TDP-43 pathology overlap with ALS, FTD, and LATE?What are the latest diagnostic criteria for TDP-43–associated neurodegeneration?What biomarkers are being developed for TDP-43–associated neurodegeneration?What biomarkers are being developed for TDP-43 proteinopathy detection in vivo?

Keep scrolling